ASEAN and China Biosimilars Market Expected to Reach $5,506.2 Million by 2025 – 3SBIO, Qilu Pharmaceutical, Novartis International, Pfizer, STADA Arzneimittel, Beijing SL Pharmaceutical, Fosun Pharmaceutical, Amgen, AstraZeneca, Teva Pharmaceutical

The ASEAN And China biosimilars market was valued at $687.6 million in 2017 and is expected to reach $5,506.2 million by 2025 with a CAGR of 29.7% during the forecast period. Biosimilars or follow-on-biologics are the "copied" version of reference biologics, which are protected by intellectual rights that are anticipated to expire in future. The development and validation of biosimilars with reference biologics is a crucial part of the overall process. The key driving factor for biosimilars is their implied ability of providing more cost-effective treatment than branded biologics.

Key players operating in the pharmaceuticals industry are largely investing in the development of biosimilars that can be applied for the treatment of several chronic medical conditions. Biosimilars have the potential to offer up to 30% cost reduction as compared to branded biologics. This is attributed to the compact validation pathways that reduce the additional cost of clinical trials, which further assist manufacturers to achieve scale economies. The key contributing factor to the growth in demand for biosimilars across the ASEAN and Chinese market is the patent expiration of most of the blockbuster drugs in the past few years. However, the biosimilars industry is witnessing issues pertaining to achieving product efficiency while maintaining the required production capacity. This plays a pivotal role in the biosimilars industry considering the large population of ASEAN countries along with China. Progress in improving the product efficiency and quantity is expected to open new avenues for the expansion of the biosimilars market across ASEAN and China.

Know More|Download Sample Copy at:

The ASEAN and China biosimilars market is segmented into molecule type, application, and region. Based on molecule type, the market is divided into human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and peptide. Based on application, the market is classified into blood disorders, oncology diseases, chronic and autoimmune diseases, growth hormone deficiency, and others. Further, the chronic and autoimmune diseases segment is sub-categorized into diabetes, rheumatoid arthritis (RA), glaucoma, and others. Based on region, the market is analyzed across China and ASEAN region.

Key Benefits ASEAN and China Biosimilars Market:

The study provides an in-depth analysis of the ASEAN and China biosimilars market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
A qualitative analysis of the driving factors and opportunities help analyze the competitive scenario of the market.
Porter's five forces analysis is provided to interpret the bargaining power of the suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.

Check for Discount at:

Table of Contents:

1 Introduction
1.1 Scope of Study
2 Key Takeaways
3 ASEAN and China Biosimilars Market Landscape
3.1 Market Overview
3.2 Market Segmentation
3.3 PEST Analysis
4 ASEAN and China Biosimilars Market- Key Industry Dynamics
4.1 Key Market Drivers
4.2 Key Market Restraints
4.3 Key Market Opportunities
4.4 Future Trends
4.5 Impact Analysis
5 ASEAN and China Biosimilars Market Analysis- Global
5.1 Global ASEAN and China Biosimilars Market Overview
5.2 Global ASEAN and China Biosimilars Market Forecasts and Analysis
5.3 Market Positioning/Market Share
5.4 Performance of Key Players
5.5 Expert Opinions ASEAN and China Biosimilars Market

Get Complete Report at:

Contact Info:
Name: Sameer Joshi
Email: [email protected]
Organization: Premium Market Insights
Phone: +1-646-491-9876

About Premium Market Insights:

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider.

Posted by on Monday September 16 2019, 3:16 AM EDT. All trademarks acknowledged. Filed under Biotechnology, Business Services, Diagnostics, Featured Press Release, Healthcare, Life Sciences, Medical Devices, Pharmaceuticals. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

News Categories

Featured Press Releases

Log in